Brief: Aptose's Tuspetinib Exceeds Expectations When Combined With Standard Of Care Treatment Across Diverse Populations Of Newly Diagnosed AML
16/10/2025 12:34
Oct 16 (Reuters) - Aptose Biosciences Inc APS.TO: APTOSE’S TUSPETINIB EXCEEDS EXPECTATIONS WHEN COMBINED WITH STANDARD OF CARE TREATMENT ACROSS DIVERSE POPULATIONS OF NEWLY DIAGNOSED AML APTOSE BIOSCIENCES INC - 88% CR/CRH RESPONSES IN FLT3 WILDTYPE AML APTOSE BIOSCIENCES INC - TUS ADDED TO VEN+AZA ACHIEVES 100% CR/CRH RESPONSES AT HIGHER DOSES APTOSE BIOSCIENCES INC - TUS+VEN+AZA WELL TOLERATED WITH NO SIGNIFICANT SAFETY CONCERNS APTOSE BIOSCIENCES INC - TUS+VEN+AZA ACHIEVES CR/CRH AND MRD-NEGATIVITY IN MUTATED AML Source text: ID:nGNX35mXdq Further company coverage: APS.TO
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting